Bayton Medipharm aims to establish Botswana's first specialised IV fluids manufacturing plant, reducing the country's reliance on imported IV fluids. The facility will utilise automated production technology to manufacture approximately 2.16 million bottles of IV fluids per month.
Project overview
Investment opportunity
An investment of US$4.86 million is being sought, excluding working capital requirements.
Investment types sought
Debt; Equity
Project status
Development stage
Structuring & preparation
Current status / progress to date
Project site secured. Offtake agreements have been secured, and financing negotiations with commercial banks are underway.
Additional project information
- Lead agency
- Bayton Medipharm
Expected impact
46
Jobs created / supported
Economic & development benefits
- Replaces imports of an essential medical product, reducing foreign exchange outflows and easing pressure on healthcare budgets
- Establishes a domestic pharmaceutical manufacturing capability and creates 46 jobs
- Creates export opportunities in neighbouring markets and supports regional trade
- Strengthens healthcare supply security through local production of IV fluids
- Supports Botswana's economic diversification agenda by expanding manufacturing beyond the mining sector
Climate & resilience benefits
- Strengthens healthcare supply security by reducing reliance on imported IV fluids and shortening supply chains
- Enhances resilience to climate-related transport disruptions, including floods and other extreme weather events
- Reduces the risk of medical supply shortages caused by global supply chain constraints
- Supports the health system's capacity to respond to climate-sensitive conditions, including heat-related illnesses, dehydration and waterborne diseases
- Improves continuity of essential healthcare services during emergencies and periods of supply disruption
Contact
Contact team
For more information about this project, please contact the Commonwealth Investment Platform team.